Fingerprint
Dive into the research topics of 'Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically